Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Deferiprone therapy for transfusional iron overload.

A Victor Hoffbrand1

  • 1Department of Haematology, Royal Free Hospital, Pond Street, London NW3 5QG, UK. v.hoffbrand@rfc.ucl.ac.uk

Best Practice & Research. Clinical Haematology
|March 2, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mandatory UK folic acid fortification.

Lancet (London, England)·2021
Same author

The Role of Deferiprone in Iron Chelation. Reply.

The New England journal of medicine·2019
Same author

The Role of Deferiprone in Iron Chelation.

The New England journal of medicine·2018
Same author

Professor John Scott, folate and neural tube defects.

British journal of haematology·2013
Same author

How I treat transfusional iron overload.

Blood·2012
Same author

X-linked sideroblastic anemia due to carboxyl-terminal ALAS2 mutations that cause loss of binding to the β-subunit of succinyl-CoA synthetase (SUCLA2).

The Journal of biological chemistry·2012

Deferiprone offers an orally active iron chelation therapy for patients with refractory anemias, addressing limitations of desferrioxamine. This oral treatment shows promise in preventing organ damage from iron overload.

Area of Science:

  • Hematology
  • Pharmacology
  • Internal Medicine

Background:

  • Iron overload is a significant complication for patients with refractory anemias requiring regular blood transfusions.
  • Existing treatment, desferrioxamine, faces challenges due to cost and administration difficulties, creating a need for alternative therapies.

Purpose of the Study:

  • To evaluate deferiprone as an orally active iron chelator for patients with iron overload.
  • To compare the efficacy and safety of deferiprone with desferrioxamine in managing iron overload.

Main Methods:

  • Clinical trials involving patients with refractory anemias receiving regular blood transfusions.
  • Administration of deferiprone at varying doses (75-100 mg/kg/day) and combination therapy with desferrioxamine.
  • Monitoring for iron overload reduction and assessment of side-effects.

Related Experiment Videos

Main Results:

  • Deferiprone is effective in chelating iron, with many patients achieving successful chelation at 75 mg/kg/day.
  • Higher doses or combination therapy may be necessary for some patients.
  • Recognized side-effects of deferiprone include agranulocytosis, neutropenia, and gastrointestinal symptoms, leading to discontinuation in only 5-10% of patients.

Conclusions:

  • Deferiprone is a viable, orally active alternative to desferrioxamine for iron chelation in specific patient populations.
  • Emerging data suggest deferiprone may offer superior cardiac protection compared to desferrioxamine.
  • Deferiprone is approved in 43 countries and may become a first-line treatment if further trials confirm its cardiac benefits.